CervoMed Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $4.0M | $9.7M | $7.1M | $0 | — |
| Operating income | -$28.3M | -$18.2M | -$7.8M | -$3.5M | -$24.7M |
| Operating expenses | $32.3M | $28.0M | $15.0M | $3.5M | — |
| Cash from operations | -$23.4M | -$16.5M | -$7.4M | -$2.6M | -$14.5M |
| Share repurchases | — | — | $0 | — | — |
| Impairments | — | — | — | $0 | $8.6M |
| Total assets | $22.9M | $43.1M | $10.0M | $4.2M | $37.8M |
| Total liabilities | $4.7M | $3.9M | $2.6M | $13.2M | $2.9M |
Shares outstanding 9.3M · Free float 100.0%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.